EP3555071A4 - Heparanase inhibitors and use thereof - Google Patents

Heparanase inhibitors and use thereof Download PDF

Info

Publication number
EP3555071A4
EP3555071A4 EP17880657.6A EP17880657A EP3555071A4 EP 3555071 A4 EP3555071 A4 EP 3555071A4 EP 17880657 A EP17880657 A EP 17880657A EP 3555071 A4 EP3555071 A4 EP 3555071A4
Authority
EP
European Patent Office
Prior art keywords
heparanase inhibitors
heparanase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17880657.6A
Other languages
German (de)
French (fr)
Other versions
EP3555071A1 (en
Inventor
Keats NELMS
Brett SCHWARTZ
Colin Jackson
Martin Banwell
Edward Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Therapeutics Pty Ltd
Original Assignee
Beta Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902346A external-priority patent/AU2017902346A0/en
Application filed by Beta Therapeutics Pty Ltd filed Critical Beta Therapeutics Pty Ltd
Publication of EP3555071A1 publication Critical patent/EP3555071A1/en
Publication of EP3555071A4 publication Critical patent/EP3555071A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP17880657.6A 2016-12-13 2017-12-13 Heparanase inhibitors and use thereof Withdrawn EP3555071A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433639P 2016-12-13 2016-12-13
AU2017902346A AU2017902346A0 (en) 2017-06-20 Methods of treating ocular disorders
PCT/AU2017/000271 WO2018107201A1 (en) 2016-12-13 2017-12-13 Heparanase inhibitors and use thereof

Publications (2)

Publication Number Publication Date
EP3555071A1 EP3555071A1 (en) 2019-10-23
EP3555071A4 true EP3555071A4 (en) 2020-06-10

Family

ID=67148292

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17880657.6A Withdrawn EP3555071A4 (en) 2016-12-13 2017-12-13 Heparanase inhibitors and use thereof

Country Status (4)

Country Link
EP (1) EP3555071A4 (en)
AU (2) AU2017376818A1 (en)
IL (1) IL267243A (en)
WO (1) WO2018107201A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210401803A1 (en) * 2018-11-21 2021-12-30 The University Of The West Indies Compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078427A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
US20080306053A1 (en) * 2007-06-08 2008-12-11 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668787A (en) * 1985-12-20 1987-05-26 Ortho Pharmaceutical Corporation 5,6-dialkoxy-4-imino-2(1H)quinazolinone derivatives
EP0594877A1 (en) * 1992-10-26 1994-05-04 National Science Council Imidazo(1,2-c)quinazoline derivates as antihyper tensives and anti dysurics
GT199900185A (en) * 1998-11-06 2001-04-18 NOVEDOSA PIRIMIDIN-4-ENAMINE AS A FUNGICIDE.
US8828952B2 (en) * 2007-10-16 2014-09-09 Progen Pharmaceuticals Limited Sulfated oligosaccharide derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078427A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
US20080306053A1 (en) * 2007-06-08 2008-12-11 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHO NAM-CHUL ET AL: "Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists", BIOORGANIC & MEDICINAL CHEMISTRY : A TETRAHEDRON PUBLICATION FOR THE RAPID DISSEMINATION OF FULL ORIGINAL RESEARCH PAPERS AND CRITICAL REVIEWS ON BIOMOLECULAR CHEMISTRY, MEDICINAL CHEMISTRY AND RELATED DISCIPLINES, ELSEVIER, NL, vol. 23, no. 24, 18 November 2015 (2015-11-18), pages 7717 - 7727, XP029342478, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2015.11.016 *
See also references of WO2018107201A1 *
WOLF-DIETHARD PFEIFFER ET AL: "Synthesis and reactivity of 1,2,4-triazolo[1,5- c ]quinazolines", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 36, no. 5, 1 September 1999 (1999-09-01), US, pages 1327 - 1336, XP055368354, ISSN: 0022-152X, DOI: 10.1002/jhet.5570360536 *

Also Published As

Publication number Publication date
AU2022201731A1 (en) 2022-04-07
IL267243A (en) 2019-08-29
EP3555071A1 (en) 2019-10-23
AU2022201731B2 (en) 2024-03-28
AU2017376818A1 (en) 2019-07-11
WO2018107201A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
EP3526222A4 (en) Tyk2 inhibitors and uses thereof
EP3471727A4 (en) Cxcr4 inhibitors and uses thereof
EP3528816A4 (en) Tyk2 inhibitors and uses thereof
EP3389658A4 (en) Glycosidase inhibitors and uses thereof
EP3472129A4 (en) Cxcr4 inhibitors and uses thereof
EP3658557A4 (en) Tyk2 inhibitors and uses thereof
EP3429591A4 (en) Substituted inhibitors of menin-mll and methods of use
EP3344624B8 (en) Tyk2 inhibitors and uses thereof
AU2015342774B2 (en) EZH2 inhibitors and uses thereof
EP3268369A4 (en) Anti-alphavbeta1 integrin inhibitors and methods of use
EP3510040A4 (en) Ectonucleotidase inhibitors and methods of use thereof
EP3303634A4 (en) Cas9 variants and methods of use thereof
EP3110820A4 (en) Tyk2 inhibitors and uses thereof
EP3262049A4 (en) Tyk2 inhibitors and uses thereof
EP3193608A4 (en) Carm1 inhibitors and uses thereof
EP3331530A4 (en) Mthfd2 inhibitors and uses thereof
EP3471726A4 (en) Cxcr4 inhibitors and uses thereof
EP3558998A4 (en) Ectonucleotidase inhibitors and methods of use thereof
GB201605126D0 (en) Inhibitors and their uses
EP3445365A4 (en) Ezh2 inhibitors and uses thereof
EP3154972A4 (en) Azamophinan derivatives and use thereof
EP3572400A4 (en) Ezh2 inhibitor and use thereof
EP3341387A4 (en) Sialyltransferase inhibitors and uses thereof
EP3336091A4 (en) Irak4 inhibitor and use thereof
EP3294705A4 (en) Ebna1 inhibitors and methods using same

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200511

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 405/06 20060101ALI20200504BHEP

Ipc: C07D 413/06 20060101ALI20200504BHEP

Ipc: A61K 31/498 20060101ALI20200504BHEP

Ipc: C07D 403/12 20060101ALI20200504BHEP

Ipc: C07D 403/06 20060101ALI20200504BHEP

Ipc: A61P 27/02 20060101ALI20200504BHEP

Ipc: C07D 413/14 20060101ALI20200504BHEP

Ipc: A61P 3/00 20060101ALI20200504BHEP

Ipc: C07D 413/12 20060101ALI20200504BHEP

Ipc: C07D 239/95 20060101ALI20200504BHEP

Ipc: C07D 403/04 20060101ALI20200504BHEP

Ipc: A61P 35/00 20060101ALI20200504BHEP

Ipc: C07D 403/14 20060101AFI20200504BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230928